A Study of E6742 in Participants With Systemic Lupus Erythematosus

Summary

The main purpose of the study is to demonstrate the efficacy based on dose response of E6742 compared with placebo as defined by the proportion of participants achieving a response using the British Isles Lupus Assessment Group (BILAG) based Composite Lupus Assessment (BICLA) with a low dose of oral corticosteroids (OCS) (prednisone or equivalent) at Week 24 in participants with systemic lupus erythematosus (SLE).

Timeline

Start

2026-03-31

Primary completion

2028-08-05

Completion

2029-03-01

Drugs

Indications